Phase 1 × Familial ependymoma × Lymphoid × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
NCT00458744 2014-08-08

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Children's Oncology Group

Phase 1 Withdrawn
NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00030108 2012-03-15

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
NCT00112619 2011-06-30

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Pediatric Brain Tumor Consortium

Phase 1 Terminated
19 enrolled
NCT00006246 2009-10-07

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Pediatric Brain Tumor Consortium

Phase 1 Completed
28 enrolled